Want to see SE:SPRINT full AI Analyst Report?

Sprint Bioscience AB (SPRINT) Price & Analysis

1 Followers

SPRINT Stock Chart & Stats

kr1.48

-kr0.03(-2.43%)

At close: Mar 06 4:00 PM EST

kr1.48

-kr0.03(-2.43%)

Day’s Range― - ―

52-Week Rangekr0.53 - kr4.59

Previous CloseN/A

Volume19.16K

Average Volume (3M)339.14K

Market Cap

kr311.27M

Enterprise Valuekr343.57

Total Cash (Recent Filing)kr93.26M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)4.1

Beta1.49

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.72

Shares Outstanding105,515,540

10 Day Avg. Volume440,224

30 Day Avg. Volume339,144

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr84.80M

Bulls Say, Bears Say

Bulls Say

Strong Profitability And MarginsThe company currently converts revenue into substantial operating and net profit, while its high gross margin indicates meaningful economics in its activities. If maintained, this profitability can support internal funding, strengthen resilience, and provide resources for continued drug discovery and partnering efforts.

Debt-free Balance SheetA debt-free balance sheet limits interest expense and financial risk, giving Sprint Bioscience greater flexibility during development cycles. The rebuilt equity base also provides a stronger foundation for advancing programs and absorbing variability in partnership timing or operating results.

Strong Current Cash GenerationCurrent operating and free cash flow closely track net income, indicating that reported profitability is translating into cash rather than remaining purely accounting-based. This supports funding for research activities and improves the company’s capacity to manage near-term development commitments.

Bears Say

Recent Revenue ContractionThe recent top-line decline suggests that current earnings strength may not yet reflect a consistently expanding revenue base. For a company dependent on licensing and partnering outcomes, weaker revenue generation can reduce operating visibility and make future results more dependent on new agreements or milestones.

Historically Volatile ProfitabilityThe sharp shift from losses to very high TTM profitability shows that earnings can vary materially between periods. Such volatility makes the current margin profile harder to treat as durable and may complicate planning, resource allocation, and assessment of sustainable earnings power.

Dependence On Partnering OutcomesThe business model relies on creating attractive preclinical assets and converting them into partnerships, upfront payments, research funding, milestones, or royalties. Delays or weak outcomes in those partnering processes could materially affect revenue timing and the company’s ability to sustain operations.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was kr0.53 and its highest was kr4.59 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is kr311.27M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is Nov 11, 2026 which is in 51 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Aug 26, 2026. The company reported -kr0.154 earnings per share for the quarter.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of -kr0.154 in its last earnings report. Following the earnings report the stock price went up 1.905%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in SE:SPRINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.